iGlarLixi vs IDegAsp in Chinese participants after OAD(s)

Trial Identifier: LPS17396
Sponsor: Sanofi
Start Date: July 2022
Primary Completion Date: October 2023
Study Completion Date: October 2023
Condition: Diabetes: Type 2

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description

Trial Locations

Country Location
CHINA Baotou, CHINA, 014010
CHINA Beijing, CHINA
CHINA Beijing, CHINA, 101200
CHINA Beijing, CHINA, 100853
CHINA Cangzhou, CHINA, 061000
CHINA Changchun, CHINA, 130021
CHINA Changchun, CHINA, 130041
CHINA Changde, CHINA, 415000
CHINA Changsha, CHINA, 410013
CHINA Chengdu, CHINA, 610081
CHINA Chengdu, CHINA, 611130
CHINA chenzhou, CHINA
CHINA Chongqing, CHINA, 400010
CHINA Dalian, CHINA, 116011
CHINA FOSHAN, CHINA, 528399
CHINA Guangzhou, CHINA, 510080
CHINA Guangzhou, CHINA, 510150
CHINA Handan, CHINA, 056002
CHINA Hangzhou, CHINA, 310014
CHINA Harbin, CHINA, 150001
CHINA Harbin, CHINA
CHINA Huai'an, CHINA, 223300
CHINA Huanggang, CHINA, 438000
CHINA Huangshi, CHINA, 435000
CHINA Huhehaote, CHINA
CHINA Huizhou, CHINA, 516001
CHINA huzhou, CHINA
CHINA Jinan, CHINA, 250013
CHINA Jinan, CHINA, 250012
CHINA Jingzhou, CHINA, 434020
CHINA Kaifeng, CHINA
CHINA Lanzhou, CHINA, 730000
CHINA Lianyungang, CHINA, 222002
CHINA Luoyang, CHINA, 471003
CHINA Nanjing, CHINA
CHINA Nanjing, CHINA, 210011
CHINA Nantong, CHINA, 226001
CHINA Pingxiang, CHINA, 337055
CHINA qingdao, CHINA, 266042
CHINA Qinhuangdao, CHINA
CHINA shanghai, CHINA
CHINA Shanghai, CHINA, 200040
CHINA Shanghai, CHINA, 201700
CHINA Shenyang, CHINA, 110004
CHINA Suzhou, CHINA
CHINA Tianjin, CHINA, 300121
CHINA Tianjin, CHINA, 300052
CHINA Tonghua, CHINA, 130000
CHINA Xingtai, CHINA, 054031
CHINA Xuzhou, CHINA
CHINA Yueyang, CHINA
CHINA Yueyang, CHINA, 414000
CHINA yuncheng, CHINA, 044000
CHINA Zhengzhou, CHINA
CHINA Zhenjiang, CHINA, 212001
CHINA Zhongshan, CHINA
CHINA Zhuzhou, CHINA, 412007
CHINA Zigong, CHINA, 643002